CBIO(CBIO)
CBIO
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $2M | $5M | $8M | $17M | $78M |
| Low | $2M | $5M | $8M | $16M | $76M |
| High | $2M | $6M | $10M | $20M | $91M |
| EBITDA Avg | $-1M | $-3M | $-5M | $-10M | $-47M |
| Low | $-1M | $-3M | $-6M | $-12M | $-55M |
| High | $-1M | $-3M | $-5M | $-10M | $-45M |
| EBIT Avg | $-1M | $-3M | $-5M | $-10M | $-47M |
| Low | $-1M | $-3M | $-6M | $-12M | $-55M |
| High | $-1M | $-3M | $-5M | $-10M | $-45M |
| Net Income Avg | $-29M | $-28M | $-32M | $-34M | $-31M |
| Low | $-32M | $-35M | $-40M | $-42M | $-38M |
| High | $-26M | $-21M | $-24M | $-33M | $-30M |
| EPS Avg | $-2.71 | $-2.84 | $-3.06 | $-3.30 | $-3.02 |
| Low | $-3.10 | $-3.37 | $-3.83 | $-4.03 | $-3.68 |
| High | $-2.50 | $-2.04 | $-2.29 | $-3.18 | $-2.90 |
| Analysts (Rev / EPS) | 6 / 4 | 4 / 3 | 6 / 5 | 4 / 1 | 3 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $357,143 | $357,143 | — | — | — | — |
| Low | $357,141 | $357,141 | — | — | — | — |
| High | $357,144 | $357,144 | — | — | — | — |
| EBITDA Avg | $-214,285 | $-214,285 | — | — | — | — |
| Low | $-214,286 | $-214,286 | — | — | — | — |
| High | $-214,284 | $-214,284 | — | — | — | — |
| EBIT Avg | $-214,285 | $-214,285 | — | — | — | — |
| Low | $-214,286 | $-214,286 | — | — | — | — |
| High | $-214,284 | $-214,284 | — | — | — | — |
| Net Income Avg | $-20M | $-21M | $-25M | $-26M | $-31M | $-30M |
| Low | $-24M | $-24M | $-25M | $-26M | $-31M | $-30M |
| High | $-18M | $-18M | $-25M | $-26M | $-31M | $-30M |
| EPS Avg | $-0.66 | $-0.69 | $-0.81 | $-0.87 | $-1.00 | $-1.00 |
| Low | $-0.80 | $-0.80 | $-0.81 | $-0.87 | $-1.00 | $-1.00 |
| High | $-0.57 | $-0.61 | $-0.81 | $-0.87 | $-1.00 | $-1.00 |
| Analysts (Rev / EPS) | 7 / 3 | 7 / 3 | — / 1 | — / 1 | — / 1 | — / 1 |